OmniAb Inc (OABI) - מזומנים למניה

OmniAb, Inc. (OABI) is scaling its B2B antibody discovery platform, attracting new partners to generate royalty streams. The cash per share data published on GURU.Markets confirms this trend, where the 0.44 mark characterizes this parameter. The business relies on unique OmniRat patents that create a high barrier to entry and grows efficiently through technology licensing without incurring manufacturing costs.
פילוחים אנליטיים של חברת OmniAb, Inc.

This indicator determines the volume of liquid assets per security, allowing for an assessment of the issuer's financial resilience to market shocks. Analyzing the annual trend of cash per share, the current value of 0.44 reflects the ability of OmniAb, Inc. (OABI) to sustain antibody development and accumulate royalties from pharma behemoths, balancing share price protection with capital efficiency.